Belite Bio, Inc (BLTE)

SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting...

The biotech's Stargardt disease drug did well in a late-stage clinical trial. This is an eye affliction that can lead to loss of central vision....

SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting...

Belite Bio, Inc (BLTE) Discusses Positive Topline Results from Phase III DRAGON Trial of Tinlarebant in Stargardt Disease Transcript...

Belite Bio Inc. (NASDAQ: BLTE) on Monday released topline results from the global Phase 3 DRAGON trial of Tinlarebant, marking the first successful pivotal trial in patients with Stargardt disease typ...

Belite Bio said on Monday that its experimental drug for a rare genetic eye disease met the main goal in a late-stage study....

SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”) today announced topline results from the global Phase 3 “DRAGON” trial of Tinlarebant, marki...

Belite Bio, Inc ( BLTE ) Q3 2025 Earnings Call November 10, 2025 4:30 PM EST Company Participants Julie Fallon Yu-Hsin Lin - Chairman of the Board of Directors & CEO Hao-Yuan Chuang - CFO & Director N...

Belite Bio, Inc ( BLTE ) Deutsche Bank ADR Virtual Investor Conference 2025 November 4, 2025 10:30 AM EST Company Participants Nathan L. Mata - Chief Scientific Officer Conference Call Participants Za...

Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as ...